ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B-Reference-Cited by-同舟云学术

ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B

Published:2018-03-06 Issue:10 Volume:38 Page:1760-1769
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Wong Darren¹²^ORCID,Littlejohn Margaret¹,Edwards Rosalind¹,Jackson Kathy¹,Revill Peter¹,Gaggar Anuj³,Kitrinos Kathryn³,Subramanian Mani³,Marcellin Patrick⁴,Buti-Ferret Maria⁵,Janssen Harry⁶,Gane Ed⁷,Locarnini Stephen¹,Thompson Alexander²

Affiliation:

1. Division of Molecular Research and Development; Victorian Infectious Diseases Reference Laboratory; Doherty Institute Melbourne; Royal Melbourne Hospital; Melbourne Vic. Australia

2. Department of Gastroenterology; St. Vincent's Hospital; Fitzroy Vic. Australia

3. Gilead Sciences; Foster City CA USA

4. Hôpital Beaujon; University of Paris; Clichy France

5. Liver Unit; Vall d'Hebron (Ciberehd) University Hospital; Barcelona Spain

6. Toronto Center for Liver Diseases; Toronto Western and General Hospital; University Health Network; University of Toronto; Toronto ON Canada

7. New Zealand Liver Transplant Unit; Auckland City Hospital; Auckland New Zealand

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13716/fullpdf

Reference26 articles.

1. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015;Wang;Lancet,2016

2. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013;Schweitzer;Lancet,2015

3. AASLD guidelines for treatment of chronic hepatitis B;Terrault;Hepatology,2016

4. EASL clinical practice guidelines: management of chronic hepatitis B virus infection;Papatheodoridis;J Hepatol,2012

5. Global strategies are required to cure and eliminate HBV infection;Revill;Nat Rev Gastroenterol Hepatol,2016

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Path to Cure Hepatitis B: How Far Are We?;Livestock Diseases and Management;2024

2. Predictive value of Th17 and Treg cells at baseline for HBsAg loss in chronic hepatitis B patients with low HBsAg quantification treated with pegylated interferon and nucleos(t)ide analogue;Liver Research;2023-06

3. CD4+ T cell counts and soluble programmed death-1 at baseline correlated with hepatitis B surface antigen decline in HIV/HBV coinfection during combined antiretroviral therapy;Frontiers in Cellular and Infection Microbiology;2023-05-03

4. Emerging anti‐HDV drugs and HBV cure strategies with anti‐HDV activity;Liver International;2023-04-05

5. PgRNA kinetics predict HBsAg reduction in pregnant chronic hepatitis B carriers after treatment cessation;Frontiers in Cellular and Infection Microbiology;2022-12-12